Cell & Gene Therapy

 

12 - 14 November 2019 | Barcelona

 

Strategy, advocacy and partnering for the orphan drug industry

 

What is Cell & Gene Therapy Orphan Drugs?

 

Over the past 10 years there has been an evolution in treatment options for rare disease patients. Cell & Gene therapies have given hope and now provide a therapeutic solution to treat & cure disease. Birthed from the World Orphan Drug Congress, which boasts 10 years of experience in the rare disease and is the largest and most established multistakeholder European orphan drug event; we have launched the Cell & Gene Therapy Co-Conference ! Join us for a spectacular 3 days in Barcelona, Spain from 12th–14th of November 2019.

The annual Cell & Gene therapy event for rare diseases will address the clinical, strategic and commercial aspects that are impacting the reality of gene therapy. Co-located with the World Orphan Drug Congress, the conference brings government authorities, payers, industry and patient advocacy groups all under one roof; with dedicated content and tracks on Cell & Gene Therapy Clinical Developments, Manufacturing (Scale Up & Delivery), Precision Medicine, Market Access, Pricing & Reimbursement.

 

Enjoy discussions on: 

Cell & Gene Therapies

Genome Editing

Clinical Trial Updates

Manufacture (Scale Up & Delivery)

Precision Medicine

Overcoming Regulatory Hurdles

Incorporating Patients into the Clinical Development Process

Market Access

Pricing & Reimbursement

Commercial Strategy

Pitch & Partner

 

Previous Speakers

 

  • Dr Segolene Ayme at World Orphan Drug Congress 2018
    Dr Segolene Ayme
    Founder of Orphanet & Rare Disease Expert in Residence
    Inserm
    Sophia Brodin at World Orphan Drug Congress 2018
    Sophia Brodin
    Deputy Head of Department, Department of Value Based Pricing
    The Dental and Pharmaceutical Benefits Agency T.L.V.
  • Anna Bucsics at World Orphan Drug Congress 2018
    Anna Bucsics
    Project Advisor
    Mechanism of Coordinated Access to orphan medicinal products (MoCA)
    Dr Andreas Busch at World Orphan Drug Congress 2018
    Dr Andreas Busch
    Chief Scientific Officer, Head of Research and Development
    Shire Pharmaceuticals
  • Avril Daly at World Orphan Drug Congress 2018
    Avril Daly
    CEO
    Retina International
    Karen Facey at World Orphan Drug Congress 2018
    Karen Facey
    Senior Research Fellow
    University of Edinburgh
  • Pamela Gavin at World Orphan Drug Congress 2018
    Pamela Gavin
    Chief Strategy Officer
    National Organization for Rare Disorders
    Edmund Jessop at World Orphan Drug Congress 2018
    Edmund Jessop
    Medical Adviser
    National Health Service
  • Dr Greg Larosa at World Orphan Drug Congress 2018
    Dr Greg Larosa
    Senior Vice President & Head of Scientific Strategy, Rare Disease RU
    Pfizer
    Yann Le Cam at World Orphan Drug Congress 2018
    Yann Le Cam
    Chief Executive Officer
    EURORDIS
  • Alastair Mackinnon at World Orphan Drug Congress 2018
    Alastair Mackinnon
    CMO
    Mereo BioPharma
    Nathalie Moll at World Orphan Drug Congress 2018
    Nathalie Moll
    Director General
    EFPIA
  • Luca Sangiori at World Orphan Drug Congress 2018
    Luca Sangiori
    Head of Medical Genetics and Rare Orthopedic Diseases
    Rizzoli Orthopaedic Institute
    Ad Schuurman at World Orphan Drug Congress 2018
    Ad Schuurman
    Senior Advisor International Affairs
    National Health Care Institute (ZIN), the Netherlands
  • Dr Josep Torrent-Farnell at World Orphan Drug Congress 2018
    Dr Josep Torrent-Farnell
    Medicines Department
    Catalan Health Service
    Dr Sander Van Deventer at World Orphan Drug Congress 2018
    Dr Sander Van Deventer
    Chief Scientific Officer And General Manager
    uniQure
  • Dr Andreas Vogel at World Orphan Drug Congress 2018
    Dr Andreas Vogel
    Head of European Regulatory
    Bluebird Bio
    Till Voigtlander at World Orphan Drug Congress 2018
    Till Voigtlander
    Vice-President of the Board of Members States on ERNs
    Medical University of Vienna

Scientific Advisory Board

 
 

Wills Hughes-Wilson, Former Senior Vice President, Chief Patient Access Officer, Sobi

Wills Hughes-Wilson  
Head of Patient Access & Commercial Planning 
Mereo Biopharma

Professor Michael Linden, Former VP Gene Therapy & Head, GMI, Pfizer

Professor Michael Linden   
Former VP Gene Therapy & Head, GMI
Pfizer

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam  
Chief Executive Officer  
EURORDIS

Dr Ségolène Aymé, Founder of Orphanet, Emeritus Research Director, INSERM

Dr Ségolène Aymé  
Founder of Orphanet, Emeritus Research Director
INSERM

Dr Bruno Sepodes, Chair of COMP, EMA

Dr Bruno Sepodes   
Chair of COMP
EMA

Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Sheela Upadhyaya
Assoc. Director Highly Specialised Technologies
National Institute For Health and Care Excellence

Alastair Kent, Director, Genetic Alliance UK

Alastair Kent
Former Director
Genetic Alliance UK

Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company

Dr Carlo Incerti
SVP, Head of Global Medical Affairs, CMO
Genzyme, A Sanofi Company

Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche

Dr Mathew Pletcher
Head of Rare Disease Discovery
Roche

Dr M Ken Kengatharan, Managing Director, Atheneos Capital

M Ken Kengatharan
Managing Partner, Atheneos Ventures and CEO
Auxesia Orion

Birgitte Volck, President Research & Development, AVROBIO

Dr Birgitte Volck
President Research & Development AVROBIO

Dr Pedro Franco, Former Scientific Administrator, EMA

Dr Pedro Franco
Former Scientific Administrator 
EMA

Rick Thompson, CEO, Findacure

Rick Thompson
CEO 
Findacure

Dr Alexander Natz, Secretary General, EUCOPE

Dr Alexander Natz
Secretary General
EUCOPE

Anna Bucsics, Project Advisor, MoCA

Anna Bucsics
Project Advisor
MoCA 

Josie Godfrey, Former Associate Director, NICE

Josie Godfrey
Former Associate Director
NICE

Dr Diego Ardigo, Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at Chiesi Group

Dr Diego Ardigo
Chair,  IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at  Chiesi Group

Steve Groft, Senior Advisor to Director, National Center for Advancing Translational Sciences (NCATS), NIH

Steve Groft
Senior Advisor to Director
National Center for Advancing Translational Sciences (NCATS), NIH

Durhane Wong-Rieger, Chair of RDI and CEO, CORD

Durhane Wong-Rieger
Chair of  RDI  and CEO,  CORD

Dr Josep Torrent-Farnell, Head of the medicine division, CatSalut

Dr Josep Torrent-Farnell
Head of the medicine division
CatSalut

2019 Agenda Overview

 

2019 Agenda Overview

Who Attends?

 

Who attends?

 

Professionals in Cell and Gene Therapy:

 
  • CEO, CSO, CMOs in Pharma and Biotech
  • Heads in:
    • R&D, Gene Therapy and Rare diseases
    • Gene Editing
    • Precision/Personalised Medicine
    • Genetic Disorders
    • Patient Advocacy and Engagement
Academic Institutions
Associations in ATMPs 
Investors
Regulatory Affairs Professionals
Governmental Bodies
Clinicians in Genetics
Bioprocess and Manufacturing Professionals in Vectors and Scale-up
Clinical Development, Gene Therapy and Rare Diseases
 

Who Should Sponsor & Exhibit?

Our sponsors & exhibitors are drawn from across the industry including:

Pharma

Biotech

CROs

Market Access

Consultancies

CMOs

Platform Technology

 

 

Why Sponsor?
 

Speaking Opportunities

If your company is interested in delivering a thought leadership, education or case study presentation at the event in the conference agenda, we have limited slots as per the following sponsorship packages. Stand alongside top orphan drug decision makers from key Pharma, Biotech, Government & Payers, Patient Advocacy Groups, Non-Profit Organisations, Academics and Research Institutions, to make sure your company is front of mind to those who matter.

Exclusive Keynote Title

Exclusive to one company only, you will have the opportunity to present in the KEYNOTE plenary alongside a handful of the very top orphan drug industry thought leaders, and to an audience of over 400 decision makers. No other company at the event will have the same chance to position itself in the same way in your area of expertise, so offering unparalleled visibility to demonstrate your offering as the leader in your field.


 

Platinum

Presenting to a more targeted orphan drug audience in your specific area of expertise, this is an exclusive opportunity to be the session lead sponsor and one of the first speakers of the relevant conference track.

Gold

If you are looking for a platform to demonstrate and educate the leading orphan drug decision makers of the full range of your services and capabilities, we have a few limited presentation opportunities within each targeted conference track to present in.

Silver

Either chair one of the conference track sessions relevant for your business or join one of the limited relevant panel discussions.

Roundtable

Opportunity to host/moderate one of the Roundtable discussions on a topic of your choice

 

Networking Reception

Opportunity to be the exclusive Networking Drinks / Dinner Reception host sponsor for the Day 1 or Day 2 evening.  Complimentary drinks will be offered for approx. 2 hours for all the attendees of the conferences to enjoy on your behalf, with an option for a full Dinner package.
Opportunity for a 5-minute opening welcome address to the reception. Banners, theming and branding will be visible throughout the reception with your logo.

Event Bags

The exclusive Delegate Bag Sponsorship enables your company to have a superior level of branding at the event, where the client can provide their own branded delegate bags, which will be carried by all attendees throughout the 3 days.
The sponsorship opportunity is limited to one sponsor only and the only information in the bag will be supplied by you, outside of the event booklet we produce and agenda information.

Event Showguide

Your company will have exclusive logo branding as the sponsor of the official show guide which all delegates will use as a reference over the 3 days for the event program, speakers, floor plan etc…   
We will print these documents with your logo added on the front and they will be handed out to all the 400+ delegates on registration on Day 1.

Facilitated Meetings

Our dedicated team of Networking Managers will work closely with you to arrange 1-2-1 business meetings at the event.  We will send out the attendee list approx. 4 weeks prior for you to choose targeted clients and we will help assist pre-event and on-site at your private reserved meeting table.

 

Event Lanyards

The exclusive Delegate Lanyard Sponsorship enables your company to have a superior level of branding at the event, where the client can provide their own branded lanyards , which will be worn by all attendees throughout the 3 days.
The sponsorship opportunity is limited to one sponsor only.

WiFi

Opportunity for your company to be branded as the exclusive WiFi Sponsor and have recognition of this on all event documentation, brochure and WiFi business card. Choice of WiFi code and branding on landing page.

Poster Zone

Opportunity for your company to be branded as the exclusive Poster Zone Sponsor and have recognition of this on all event documentation and brochure.  Banners with your logo will be positioned around the Poster Zone area.

 

 

DOWNLOAD PROSPECTUS

Follow us on

 

Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2019

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
t/ +44 20 7092 5945

 

To Speak

 

Wing-Yun Cheung
wing-yun.cheung@terrapinn.com
t/ +44 20 7092 1172

 

To Register

 

Issa Mauthoor
issa.mauthoor@terrapinn.com
t/ +44 20 7092 1257